Abraxis: new pharmaceutical formulations and Article 3(d) SPC Regulation

By Signoroni S.

Abstract

Abraxis Bioscience LLC v Comptroller General of Patents, Case C-443/14, Court of Justice of the European Union, 21 March 2019The Court of Justice of the European Union ruled that a marketing authorization (MA) granted for a new formulation of an old active ingredient cannot be considered the first MA granted …read more

Source:: Journal of Intellectual Property Law & Practice